作者:Francesco Mesiti、Alexandra Gaspar、Daniel Chavarria、Annalisa Maruca、Roberta Rocca、Eva Gil Martins、Sandra Barreiro、Renata Silva、Carlos Fernandes、Sheraz Gul、Oliver Keminer、Stefano Alcaro、Fernanda Borges
DOI:10.1021/acs.jmedchem.1c00510
日期:2021.8.12
Chromone-3-phenylcarboxamides (Crom-1 and Crom-2) were identified as potent, selective, and reversible inhibitors of human monoamine oxidase B (hMAO-B). Since they exhibit some absorption, distribution, metabolism, and excretion (ADME)-toxicity liabilities, new derivatives were synthesized to map the chemical structural features that compose the pharmacophore, a process vital for lead optimization. Structure–activity
Chromone-3-phenylcarboxamides(Crom-1和Crom-2)被鉴定为人类单胺氧化酶 B ( h MAO-B) 的有效、选择性和可逆抑制剂。由于它们表现出一些吸收、分布、代谢和排泄 (ADME) 毒性倾向,因此合成了新的衍生物来绘制构成药效团的化学结构特征,这是对先导优化至关重要的过程。分子对接研究支持的结构-活性关系数据为杂环的刚性、羰基和苯并吡喃杂原子对h MAO-B 抑制活性的贡献提供了基本原理。从研究中,N -(3-氯苯基)-4 H-thiochromone-3-carboxamide ( 31 ) ( h MAO-B IC 50 = 1.52 ± 0.15 nM) 作为可逆的紧密结合抑制剂出现,具有改进的药理学特征。在体外ADME 毒性研究中,化合物31在 Caco-2、SH-SY5Y、HUVEC、HEK-293 和 MCF-7 细胞中显示出安全的细胞毒性特征,不呈现心脏毒性作用,也不影响